Learn about the TargetTau-1 clinical study.
Are you or someone you know experiencing early symptoms of memory loss (mild cognitive impairment) or Alzheimer’s disease?
While there is no known cure for Alzheimer’s disease (AD), scientists have made huge progress in understanding AD and finding new routes for treatment, which can be achieved through clinical trials.
We are recruiting participants for the TargetTau-1 study. This clinical research study is testing a new, investigational medicine for mild cognitive impairment or mild early AD.
You may qualify for this study if you:
- Are 50-80 years old
- Have a diagnosis of mild cognitive impairment due to Alzheimer’s disease, or have mild Alzheimer’s dementia
- Have a study partner with whom you spend at least 8 hours per week (such as a spouse, friend, or an adult child) who can attend some study visits with you during the study and provide follow-up information.
The study doctor will also check other eligibility requirements.
Participation in the study lasts about 2 years and requires regular visits to the research clinic to receive study drug and monitor your health and AD status. If you decide to take part in the study, all study-related drugs and procedures will be provided to you at no cost. Participation is voluntary and you would be able to leave the study at any point. To learn more and see if you are eligible, please contact: 786-772-0510
To learn more about this Alzheimer’s disease clinical study, visit: bmsclinicaltrials.com/TargetTau1
